Showing results (161-170 of 410) with videos related to

Sort By:
Pageof 41
Journal for Immunotherapy of Cancer|May 19, 2025
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trialJason J Luke, Katherine Bever, F Stephen Hodi, et al.
Cancer Immunology Research|September 20, 2023
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint BlockadeSaba Tabasum, Dinesh Thapa, Anita Giobbie-Hurder, et al.
Blood Advances|August 25, 2021
Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index caseLivius Penter, Satyen H Gohil, Teddy Huang, et al.
Cancer Immunology Research|April 5, 2017
Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma PatientsMarlene Garcia-Neuer, Melina E Marmarelis, Sushrut R Jangi, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 19, 2017
RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMABGrenye O'Malley, Hanna J Lee, Samir Parekh, et al.
Annals of the New York Academy of Sciences|June 19, 2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanomaJedd D Wolchok, F Stephen Hodi, Jeffrey S Weber, et al.
Cancers|May 14, 2022
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced MelanomaKrisztian Homicsko, Reinhard Dummer, Christoph Hoeller, et al.
Journal for Immunotherapy of Cancer|August 29, 2024
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumabAnna K Maloney, Anita Giobbie-Hurder, Nikita Katukota, et al.
JCI Insight|June 3, 2020
Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapyPei-Hsuan Chen, Mikel Lipschitz, Jason L Weirather, et al.
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.
Pageof 41